Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phenytoin-induced chronic hepatitis.

Literature DB >> 8462373

Phenytoin-induced chronic hepatitis.

Abstract

Phenytoin has been associated with acute hepatotoxicity. Chronic liver enzyme abnormalities associated with phenytoin have been attributed to enzyme induction. There have been no reports of phenytoin-induced chronic hepatitis. We describe an asymptomatic 52-year-old woman who received phenytoin sodium for 11 years and was found to have elevated serum aminotransferases. Assays for hepatitis A, B, and C were negative. Liver biopsy was performed and showed chronic persistent hepatitis. This documentation of phenytoin-induced chronic persistent hepatitis was proven by histology and its etiology confirmed by drug withdrawal and by rechallenge. Although uncommon, this entity is important to recognize in the differential diagnosis of asymptomatic chronic hepatic enzyme dysfunction.

Entities: Chemical Disease Species

Mesh：

Substances：
Phenytoin

Year: 1993 PMID： 8462373 DOI： 10.1007/bf01316808

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

12 in total

1. [Chronic active hepatitis caused by diphenylhydantoin].

Authors: J R Riera Velasco; L R Rodrigo Sáez; R Pérez Alvarez; M González González
Journal: Med Clin (Barc) Date: 1986-06-28 Impact factor: 1.725

2. Diphenylhydantoin--induced hepatic necrosis.

Authors: G J Dhar; C A Pierach; P N Ahamed; R B Howard
Journal: Postgrad Med Date: 1974-07 Impact factor: 3.840

3. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

Authors: C J Doecke; M E Veronese; S M Pond; J O Miners; D J Birkett; L N Sansom; M E McManus
Journal: Br J Clin Pharmacol Date: 1991-02 Impact factor: 4.335

4. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.

Authors: M E Veronese; P I Mackenzie; C J Doecke; M E McManus; J O Miners; D J Birkett
Journal: Biochem Biophys Res Commun Date: 1991-03-29 Impact factor: 3.575

5. Cholestatic liver dysfunction after long-term phenytoin therapy.

Authors: J W Taylor; M N Stein; M J Murphy; F A Mitros
Journal: Arch Neurol Date: 1984-05

6. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions.

Authors: J S Leeder; R J Riley; V A Cook; S P Spielberg
Journal: J Pharmacol Exp Ther Date: 1992-10 Impact factor: 4.030

7. Predisposition to phenytoin hepatotoxicity assessed in vitro.

Authors: S P Spielberg; G B Gordon; D A Blake; D A Goldstein; H F Herlong
Journal: N Engl J Med Date: 1981-09-24 Impact factor: 91.245

8. Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases.

Authors: F G Mullick; K G Ishak
Journal: Am J Clin Pathol Date: 1980-10 Impact factor: 2.493

9. Cholestatic liver disease associated with diphenylhydantoin therapy. Possible pathogenic importance of altered bile salt metabolism.

Authors: C B Campbell; C McGuffie; A P Weedon; L W Powell
Journal: Am J Dig Dis Date: 1977-03

Phenytoin-induced chronic hepatitis.

1. [Chronic active hepatitis caused by diphenylhydantoin].

2. Diphenylhydantoin--induced hepatic necrosis.

3. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

4. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.

5. Cholestatic liver dysfunction after long-term phenytoin therapy.

6. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions.

7. Predisposition to phenytoin hepatotoxicity assessed in vitro.

8. Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases.

9. Cholestatic liver disease associated with diphenylhydantoin therapy. Possible pathogenic importance of altered bile salt metabolism.

10. The effects of phenobarbital and diphenylhydantoin on liver function and morphology.

Review 1. Drug-induced liver injury: is it somehow foreseeable?

Review 2. Gastrointestinal Side Effects of Antiarrhythmic Medications: A Review of Current Literature.

Review 3. Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

4. Phenytoin-induced chronic liver enzyme elevation and hepatic fibrosis: A case report.